Vasopressor use in septic shock: An update

Current Opinion in Anaesthesiology

Volumn 21, Issue 2, 2008, Pages 141-147

  Leone, Marc ^a   Martin, Claude ^a  

^a HÔPITAL NORD   (France)

Author keywords

Catecholamines; Dopamine; Epinephrine; Norepinephrine; Terlipressin; Vasopressin

Indexed keywords

ADRENALIN; ARGIPRESSIN; DOBUTAMINE; DOPAMINE; HYPERTENSIVE AGENT; ISOPRENALINE; NORADRENALIN; PLACEBO; TERLIPRESSIN; VASOPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ADRENERGIC SYSTEM; BLOOD FLOW; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SYNTHESIS; HEART INDEX; HEMODYNAMICS; HUMAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SEPTIC SHOCK; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; PATHOPHYSIOLOGY;

HUMANS; RESUSCITATION; SHOCK, SEPTIC; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 43249109414     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3282f46d20     Document Type: Review

References (79)

1. Bauer PR. Microvascular responses to sepsis: clinical significance. Pathophysiology 2002; 8:141-148.
2. Sladen RN, Landry D. Renal blood flow regulation, autoregulation, and vasomotor nephropathy. Anesthesiol Clin North America 2000; 18:791-807.
3. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2008; 36:296-327.
4. Pinsky MR, Teboul JL. Assessment of indices of preload and volume responsiveness. Curr Opin Crit Care 2005; 11:235-239.
5. Bourgoin A, Leone M, Delmas A, et al. Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 2005; 33:780-786.
6. LeDoux D, Astiz ME, Carpati CM, et al. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 2000; 28:2729-2732.
7. Bateman RM, Sharpe MD, Ellis CG. Bench-to-bedside review: microvascular dysfunction in sepsis-hemodynamics, oxygen transport, and nitric oxide. Crit Care 2003; 7:359-373.
8. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356:2139-2143.
9. Meier-Hellmann A, Bredle DL, Specht M, et al. The effects of low-dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock. Intensive Care Med 1997; 23:31-37.
10. Cronin RA, Erickson M, De Torrente A, et al. Norepinephrine- induced acute renal failure: a reversible ischemic model of acute renal failure. Kidney Int 1978; 14:187-190.
11. Schott CA, Gray GA, Stoclet JC. Dependence of endotoxin-induced vascular hyporeactivity on extracellular L-arginine. Br J Pharmacol 1993; 108:38-43.
12. Albanese J, Leone M, Garnier F, et al. Renal effects of norepinephrine in septic and nonseptic patients. Chest 2004; 126:534-539.
13. Desjars P, Pinaud M, Potel G, et al. A reappraisal of norepinephrine therapy in human septic shock. Crit Care Med 1987; 15:134-137.
14. Meadows D, Edwards JD, Wilkins RG, et al. Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 1988; 16:663-666.
15. Martin C, Eon B, Saux P, et al. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990; 18:282-285.
16. Desjars P, Pinaud M, Bugnon D, et al. Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1990; 18: 1048-1049.
17. Rudis MI, Basha MA, Zarowitz BJ. Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 1996; 24:525-537.
18. Redl-Wenzel EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993; 19:151-154.
19. Sennoun N, Montemont C, Gibot S, et al. Comparative effects of early versus delayed use of norepinephrine in resuscitated endotoxic shock. Crit Care Med 2007; 35:1736-1740.
20. In an experimental model, the authors showed that the early administration of norepinephrine was associated with a higher blood flow redistributed to the mesenteric area, lower lactate levels, and less infused volume.
21. Morimatsu H, Singh K, Uchino S, et al. Early and exclusive use of norepinephrine in septic shock. Resuscitation 2004; 62:249-254.
22. Moran JL, O'Fathartaigh MS, Peisach AR, et al. Epinephrine as an inotropic agent in septic shock: a dose-profile analysis. Crit Care Med 1993; 21: 70-77.
23. Meier-Hellmann A, Reinhart K, Bredle DL, et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997; 25:399-404.
24. Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103:1826-1831.
25. Martin C, Viviand X, Leone M, Thirion X. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000; 28:2758-2765.
26. Levy B, Dusang B, Annane D, et al. Cardiovascular response to dopamine and early prediction of outcome in septic shock: a prospective multiple-center study. Crit Care Med 2005; 33:2172-2177.
27. Sakr Y, Rheinart K, Vincent JL, et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients. Crit Care Med 2006; 34:589-597.
28. De Backer D, Creteur J, Silva E, et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 2003; 31:1659-1667.
29. Joly LM, Monchi M, Cariou A, et al. Effects of dobutamine on gastric mucosal perfusion and hepatic metabolism in patients with septic shock. Am J Respir Crit Care Med 1999; 160:1983-1986.
30. Martin C, Viviand X, Arnaud S, et al. Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients. Crit Care Med 1999; 27:1708-1713.
31. Duranteau J, Sitbon P, Teboul JL, et al. Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock. Crit Care Med 1999; 27:893-900.
32. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997; 23:282-287.
33. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007; 370:676-684.
34. The study was aimed at comparing epinephrine alone and a combination of norepinephrine and dobutamine. There was no evidence for a difference in efficacy and safety between epinephrine alone and a combination of norepinephrine and dobutamine in the management of septic shock patients.
35. Myburgh J, Higgins L, Jovanovska A, et al. A comparative of epinephrine and norepiphrine on resolution shock [abstract]. Intensive Care Med 2007; 33 (Suppl 2): S197.
36. Takakura K, Taniguchi T, Muramatsu I, et al. Modification of alpha 1-adrenoreceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 2002; 30:894-899.
37. Delmas A, Leone M, Rousseau S, et al. Vasopressin and terlipressin in septic shock patients. Crit Care 2004; 9:212-222.
38. Barrett LK, Singer M, Clapp LH. Vasopressin mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007; 35:310-312.
39. A brightening review on the mechanism of action of vasopressin on the vasculature.
40. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002; 30:497-500.
41. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125.
42. Leone M, Boyle WA. Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions. Crit Care Med 2006; 34:1126-1130.
43. SegarraG, Medina P, Vila JM, et al. Increased contraction to noradrenaline by vasopressin in human renal arteries. J Hypertens 2002; 20:1373-1379.
44. Barret LK, Orie NN, Taylor V, et al. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis. Crit Care Med 2007; 35:2337-2343.
45. In a long-term animal model, the authors show the preservation of vasopressinmediated smooth vessel muscle contraction in sepsis.
46. Hollenberg SM, Tangora JJ, Piotrowski MJ, et al. Impaired microvascular vasoconstrictive responses to vasopressin in septic rats. Crit Care Med 1997; 25:869-873.
47. Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47:699-703.
48. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29:487-493.
49. Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001; 27:1416-1421.
50. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313-2319.
51. Obritsch MD, Jung R, Fish DN, MacLaren R. Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 2004; 38: 1117-1122.
52. Hall LG, Oyen LJ, Taner CB, et al. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy 2004; 24:1002-1012.
53. Klinzing S, Simon M, Reinhart K, et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003; 31:2646-2650.
54. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96:576-582.
55. LucknerG, MayrVD, JochbergerS, et al. Comparison of two dose regimens of arginine vaopressin in advanced dilatory shock. Crit Care Med 2007; 35: 2280-2285.
56. In a retrospective study, the authors show that AVP dosages of 0.067 IU/min seem to be more efficient at reversing cardiovascular failure in vasodilatory shock requiring norepinephrine than 0.033 IU/min.
57. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359:1209-1210.
58. Leone M, Albanese J, Delmas A, et al. Terlipressin in catecholamine-resistant septic shock patients. Shock 2004; 22:314-319.
59. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catechol amine-treated hyperkinetic septic shock. Intensive Care Med 2004; 30:597-604.
60. Albanèse J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 2005; 33:1897-1902.
61. Pesaturo AB, Jennings HR, Voils SA. Terlipressin: Vasopressin analog and novel drug for septic shock. Ann Pharmacother 2006; 40:2170-2177.
62. Lange M, Morelli A, Ertmer C, et al. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 2007; 28:623-629.
63. Michel F, Thomachot L, David M, et al. Continuous low-dose infusion of terlipressin as a rescue therapy in meningococcal septic shock. Am J Emerg Med 2007; 25:863.
64. Broking K, Lange M, Morelli A, et al. Employing dobutamine as a useful agent to reverse the terlipressin-linked impairments in cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep. Shock 2008; 29:71-77.
65. In this experimental study, the authors were able to reverse the unwanted side effects of terlipressin with dobutamine in a dosage of 2 jxg/kg/min.
66. Albert M, Losser MR, Hayon D, et al. Systemic and renal macro-and microcirculatory responses to arginine vasopressin in endotoxic rabbits. Crit Care Med 2004; 32:1891-1898.
67. Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004; 32:1327-1331.
68. Laszlo FA, Laszlo F Jr, De Wield D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 1991; 43:73-108.
69. Liard JF, Deriaz O, Schelling P, et al. Cardiac output distribution during vasopressin infusion or dehydration in conscious dogs. Am J Physiol 1982; 243:H663-H669.
70. Altura BM. Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal. J Pharmacol Exp Ther 1975; 193:413-423.
71. Kerr JC, Jain KM, Swan KG, et al. Effects of vasopressin on cardiac output and its distribution in the subhuman primate. J Vasc Surg 1985; 2:443-449.
72. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane metaanalysis. Gastroenterology 2003; 124:1277-1291.
73. Van Haren FM, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003; 124:2256-2260.
74. Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 2003; 97:1756-1763.
75. Hiltebrand LB, Krejci V, Jakob SM, et al. Effects of vasopressin on micro-circulatory blood flow in the gastrointestinal tract in anesthetized pigs in septic shock. Anesthesiology 2007; 106:1156-1167.
76. In an experimental pig model, vasopressin decreased regional flow in the superior mesenteric artery and microcirculatory blood flow in the upper gastrointestinal tract.
77. MicekST, Shah P, Hollands JM, et al. Addition of vasopressin to norepinephrine as independent predictor of mortality in patients with refractory septic shock: an observational study. Surg Infect (Larchmt) 2007; 8:189-200.
78. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebocontrolled, double-blind study on the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30.
79. Hidaka T, Tsuneyoshi I, Boyle WA 3rd, et al. Marked synergism between vasopressin and angiotensin II in a human isolated artery. Crit Care Med 2005; 33:2613-2620.